Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room

Sponsor
Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
Study ID
NCT06178822
Status
Recruiting
Apply to this trial

Conditions

  • Infection Viral
  • Infection, Bacterial
  • Infections
  • Infections, Respiratory
  • Sepsis
  • Sepsis, Severe
  • Septic Shock

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • No intervention — OTHER
    There is no intervention

Study Details

Objectives: 1. To compare the immune response of patients with or without sepsis presenting to the ED with a(n) (suspected) infection. 2. To determine immune response aberrations that are associated with an increased risk of developing sepsis in patients presenting to the ED with a(n) (suspected) infection without sepsis. 3. To determine the long term cognitive and physical sequelae of sepsis after admission.

Key Dates

First listed
Dec 21, 2023
Start date
Oct 25, 2022
Status verified
Feb 2025
Primary completion
Oct 1, 2026
Completion
Oct 1, 2026

Study Design

Enrollment
3,300 participants (estimated)

Arms

  • Arm: Patients with infection
    Patients with an (suspected) infection and a MEWS score 2 or higher

Primary Outcome Measure

Final diagnosis for hospitalization [ Time Frame: 4 years ]

Central Contacts

Related Studies